Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Enforcement To Be More "Swift, Aggressive" As Centers Share Techniques

Executive Summary

FDA's ramped up enforcement efforts will include a much more collaborative approach between the agency's centers, staffers told the Food and Drug Law Institute meeting on enforcement in Washington Oct. 13

You may also be interested in...

Cornerstone’s Hyponatremia Therapy Lixivaptan Will Get Advisory Panel Scrutiny

The hyponatremia drug is a selective vasopressin V2-receptor antagonist, like Astellas’ Vaprisol and Otsuka’s Samsca.

Hamburg Offers "Close Out" Carrot To Firms In Plan To Accelerate Enforcement

FDA enforcement initiative eliminates requirement for all warning letters to be reviewed by Office of Chief Counsel.

FDA Ad Enforcement Steams On; Are “Days Of Pushing The Envelope” Over?

FDA's aggressive enforcement of its advertising standards, and the agency's new enforcement allies, mean that industry may now have more to fear from a citation letter





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts